Jul 19, 2023 / 04:00PM GMT
Operator
Thank you for standing by, and welcome to the PTC Therapeutics' PKU Deep Dive. (Operator Instructions) As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Kylie O'Keefe, Chief Commercial Officer. Please go ahead.
Kylie O'Keefe - PTC Therapeutics, Inc. - Chief Commercial Officer
Hello, everyone, and thank you for joining today's call. We are excited to share with you this presentation on PKU and our product, sepiapterin. Before I begin, I refer you to our forward-looking statements on this slide, which are also posted on our website as well as our Risk Factors section in our most recent 10-K.
Let me now begin by introducing our presenters. First, I am joined by Dr. Matthew Klein, our Chief Executive Officer; second, I'm joined by Professor Ania Muntau, a German pediatrician.
Ania was awarded her MD degree from Ludwig-Maximilians University in Munich, Germany in 1992, where she also received her postgraduate training in pediatrics. Since 2014, she has headed the clinic
PTC Therapeutics Inc Phenylketonuria (PKU) and Sepiapterin - Corporate Call Transcript
Jul 19, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers